Arthur W Castle

US Patent:

7426441, Sep 16, 2008

Filed:

Jan 18, 2005

Appl. No.:

11/036196

Inventors:

Donna Mendrick - Gaithersburg MD, US
Mark Porter - Gaithersburg MD, US
Kory Johnson - Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Arthur Castle - Gaithersburg MD, US
Michael Elashoff - Gaithersburg MD, US

Assignee:

Ocimum Biosolutions, Inc. - Indianapolis IN

International Classification:

G06F 19/00

US Classification:

702 19, 435 6, 700 30, 702 22, 7071041

Abstract:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

US Patent:

7447594, Nov 4, 2008

Filed:

Jan 8, 2003

Appl. No.:

10/338044

Inventors:

Donna L. Mendrick - Gaithersburg MD, US
Mark W. Porter - Gaithersburg MD, US
Kory R. Johnson - Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Arthur Castle - Gaithersburg MD, US
Michael Elashoff - Gaithersburg MD, US

Assignee:

Ocimum Biosolutions, Inc. - Indianapolis IN

International Classification:

G06F 19/00

US Classification:

702 19, 435 6, 700 30, 702 22, 7071041

Abstract:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known cardiotoxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

US Patent:

7469185, Dec 23, 2008

Filed:

Feb 4, 2003

Appl. No.:

10/357507

Inventors:

Donna L. Mendrick - Gaithersburg MD, US
Mark W. Porter - Gaithersburg MD, US
Kory R. Johnson - Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Arthur L. Castle - Gaithersburg MD, US
Michael Orr - Gaithersburg MD, US
Michael R. Elashoff - Gaithersburg MD, US

Assignee:

Ocimum Biosolutions, Inc. - Indianapolis IN

International Classification:

G06F 19/00

US Classification:

702 19, 435 6, 700 30, 702 22, 7071041

Abstract:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

US Patent:

7590493, Sep 15, 2009

Filed:

Feb 17, 2005

Appl. No.:

11/059535

Inventors:

Donna Mendrick - Gaithersburg MD, US
Mark Porter - Gaithersburg MD, US
Kory Johnson - Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Arthur Castle - Gaithersburg MD, US
Michael Elashoff - Gaithersburg MD, US

Assignee:

Ocimum Biosolutions, Inc. - Indianapolis IN

International Classification:

G06F 19/00

US Classification:

702 19, 435 6, 700 30, 702 22, 7071041

Abstract:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

US Patent:

20020119462, Aug 29, 2002

Filed:

Jul 31, 2001

Appl. No.:

09/917800

Inventors:

Donna Mendrick - Mount Airy MD, US
Mark Porter - Germantown MD, US
Kory Johnson - Bethesda MD, US
Arthur Castle - Washington DC, US
Michael Elashoff - Germantown MD, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

US Patent:

20020192671, Dec 19, 2002

Filed:

Jan 23, 2002

Appl. No.:

10/052547

Inventors:

Arthur Castle - Washington DC, US
Michael Elashoff - Germantown MD, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

A method for assessing toxicity and toxicology of a substance is disclosed comprising: exposing a set of at least two genes to the substance; monitoring the response of each gene in the set of genes to the substance; analyzing the variance of the response to the substance for each gene using contrast analysis; constructing a summary score for each gene in the set of genes; performing a logistic regression analysis upon the summary scores; and using the results of the logistic regression analysis to provide a predictive model regarding the toxicity and toxicology of the substance.

US Patent:

20040014040, Jan 22, 2004

Filed:

Jul 10, 2002

Appl. No.:

10/191803

Inventors:

Donna Mendrick - Gaithersburg MD, US
Mark Porter - Gaithersburg MD, US
Kory Johnson - Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Arthur Castle - Gaithersburg MD, US
Michael Elashoff - Gaithersburg MD, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known cardiotoxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

US Patent:

20040043405, Mar 4, 2004

Filed:

Jul 17, 2003

Appl. No.:

10/620765

Inventors:

Arthur Castle - Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Michael Elashoff - Gaithersburg MD, US
Mark Porter - Gaithersburg MD, US

Assignee:

Gene Logic, Inc.

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

The present invention includes methods of identifying genes whose expression level is invariant among cell or tissue types. The methods of the invention can be used in the diagnosis of disease, in quality control in evaluating external data or databases, and in normalization of external data for comparative purposes. The genes of the invention can be used to produce microarrays that generate data with improved reliability.